ライフサイエンスコーパス: coronary lesion

1 coronary catheter with the tip distal to the coronary lesion.

2 relationship to the location of the culprit coronary lesion.

3 ances were preserved by the territory of the coronary lesion.

4 ation (Hosmer-Lemeshow P=0.540) for an acute coronary lesion.

5 /=0.8 was regarded to indicate a significant coronary lesion.

6 gold standard for a hemodynamic significant coronary lesion.

7 tion fraction <40%), as well as more complex coronary lesions.

8 performed in 689 patients with 1,639 native coronary lesions.

9 tage of stenosis, and the development of new coronary lesions.

10 vascular ultrasound-guided stenting of 1,015 coronary lesions.

11 e best method for interrogating intermediate coronary lesions.

12 tal stents (BMS) in the treatment of de novo coronary lesions.

13 trasound analysis was performed in 46 native coronary lesions.

14 stenosis after stent implantation in de novo coronary lesions.

15 ice-independent relationships seen in native coronary lesions.

16 he preferred treatment for heavily calcified coronary lesions.

17 nlargement commonly (54%) occurs at stenotic coronary lesions.

18 ide anatomic and hemodynamic significance of coronary lesions.

19 st among patients with left main and complex coronary lesions.

20 stenosis in moderately to severely calcified coronary lesions.

21 r revascularization due to the recurrence of coronary lesions.

22 included, of which 163 (40%) had significant coronary lesions.

23 was identified as a predictor of significant coronary lesions.

24 tent IVOCT image data were obtained from 110 coronary lesions.

25 vulnerable plaque phenotypes to more stable coronary lesions.

26 performance for the presence of significant coronary lesions.

27 gorithm detected, quantified, and classified coronary lesions.

28 ic severity of angiographically intermediate coronary lesions.

29 tion for the treatment of severely calcified coronary lesions.

30 nt interventional tool for heavily calcified coronary lesions.

31 lanned stent implantation in de-novo, native coronary lesions.

32 drug-eluting stents implantation in de novo coronary lesions.

33 ly identified necrotic core in ex vivo human coronary lesions.

34 iveness of IVL in severely calcified de novo coronary lesions.

35 es, of functionally significant intermediate coronary lesions.

36 curate in detecting functionally significant coronary lesions.

37 FFR was </=0.80 in 54 of 144 (38%) coronary lesions.

38 the gold standard for assessing intermediate coronary lesions.

39 stigated the predictive factors for unstable coronary lesions.

40 tual histology IVUS and FFR for intermediate coronary lesions.

41 ve, more targeted treatment of KD to prevent coronary lesions.

42 icient mice were protected from LCWE-induced coronary lesions.

43 simple and medium complexity single de novo coronary lesions.

44 vascular smooth muscle cells in the advanced coronary lesions.

45 tional cardiology for treatment of calcified coronary lesions.

46 t natural history trajectories of individual coronary lesions.

47 ding treatment of patients with intermediate coronary lesions.

48 -IV trial, 1314 patients with single de novo coronary lesions 10 to 28 mm in length, with reference-v

49 A total of 1,314 patients with coronary lesions 10- to 28-mm long in 2.5- to 3.75-mm ve

50 vent (n = 131 of 264), mostly related to new coronary lesions (17.3% vs. 7.8%; p = 0.01; hazard ratio

51 bstudy enrolled 241 patients with 263 native coronary lesions (201 PES, 62 BMS) with baseline and 13-

52 tion myocardial infarction but have residual coronary lesions; (3) patients who have suffered a non-S

53 y II included fewer left anterior descending coronary lesions (46.5% vs. 32.8%, p < 0.01), more type

54 Regression of human coronary lesions after 5 weeks of treatment with apoA-I(

55 on angioplasty was performed in 1,266 native coronary lesions alone (n = 541) or after extraction ath

56 rediction model for the presence of an acute coronary lesion among patients resuscitated from an arre

57 Significant coronary lesions and 30-day mortality.

58 y should be favored in patients with complex coronary lesions and anatomy and PCI in less complicated

59 ogical significance of intermediate severity coronary lesions and cases with inadequate image quality

60 ts who underwent intervention of 2780 native coronary lesions and had complete high-quality preinterv

61 the hemodynamic significance of intermediate coronary lesions and is recommended by guideline committ

62 lectrocardiograms for predicting significant coronary lesions and mortality in patients with successf

63 ure, minimum lumen diameter (MLD), number of coronary lesions and total occlusions were not significa

64 c patients or those with ischaemia-producing coronary lesions, and reduces ischaemia to a greater ext

65 anatomic and morphologic characteristics of coronary lesions, and their comparative performance in p

66 sclerosis, BMI, as well as CRP and number of coronary lesions, are independently associated with acut

67 n of the disease through repeated use as new coronary lesions arise.

68 mise to substantially increase physiological coronary lesion assessment in the catheterization labora

69 CFI was proportional to severity of the coronary lesion at baseline (r=0.63, P<0.0001) but not 6

70 antation in a broad cross section of de novo coronary lesions at 1 year are unknown.

71 We randomized 704 patients with bifurcation coronary lesions at 58 centers (30 from Europe and 28 fr

72 ne to concluding angiogram of all qualifying coronary lesions averaged for each patient.

73 e effective in reducing restenosis in simple coronary lesions, but the evidence base for contemporary

74 ned anatomic and hemodynamic assessment of a coronary lesion by a single noninvasive test.

75 hology and composition of culprit and stable coronary lesions by multidetector computed tomography (M

76 ention remodeling was assessed in 108 native coronary lesions by using intravascular ultrasound (IVUS

77 The mean number of coronary lesions causing 30% to 75% diameter stenosis wa

78 quent restenosis rates at 6 months in native coronary lesions (CAVEAT I, 50.8% for intimal resection

79 s the prediction of functionally significant coronary lesions compared with visual CTCA assessment bu

80 shed by clinical variables, they had greater coronary lesion complexity by American Heart Association

81 atus alone and for treatment by DM status by coronary lesion complexity.

82 Similar to human lesions, the coronary lesions contain macrophages, activated mDCs, an

83 ional registry of patients with intermediate coronary lesions, defined as 40% to 80% stenosis by angi

84 The management of intermediate coronary lesions, defined by a diameter stenosis of 40%

85 In total, 144 coronary lesions detected on CTCA were visually graded f

86 In the placebo group, new coronary lesions developed in 21 of 38 smokers and in 28

87 nt elevations on the presence of significant coronary lesions (diagnostic performance) and 30-day mor

88 basis that the majority of these individual coronary lesions do not in fact go on to cause clinical

89 nonsubjective method to diagnose significant coronary lesions during MR stress testing.

90 ) with each other or against BMS for de novo coronary lesions, enrolling at least 100 patients and wi

91 Plaque rupture occurs if stress within coronary lesions exceeds the protection exerted by the f

92 -elevation MI (STEMI) patients with advanced coronary lesions expressed higher SYK and KMT5A gene lev

93 accuracy for the detection of flow-limiting coronary lesions (FFR</=0.80) was compared with visual C

94 were the frequency of detecting significant coronary lesions for which there are AHA class 1 indicat

95 cium channel-blocking agents may prevent new coronary lesion formation, the progression of minimal le

96 n vascular and extravascular tissues promote coronary lesion formation.

97 We stained multiple coronary lesions from 24 randomly selected patients who

98 Sixty-seven stented coronary lesions from 59 patients who presented with ACS

99 ally colocalized to apoptotic VSMCs in human coronary lesions, further supporting a functional role f

100 ation (h2=0.51+/-0.17; P=0.001), and ectatic coronary lesions (h2=0.52+/-0.07; P=0.001).

101 ry muscle infarction (papMI) and the culprit coronary lesion has not been fully investigated.

102 ercutaneous revascularization of significant coronary lesions has been the routine strategy in TAVR c

103 Although effective coverage of challenging coronary lesions has warranted the use of overlapping dr

104 Complex coronary lesions have higher ESS compared to simple lesi

105 n be utilized in treating severely calcified coronary lesions; however, the temporal trends, patient

106 rasound imaging was used to study 212 native coronary lesions in 209 patients after percutaneous tran

107 .3 months) IVUS was used to study 251 native coronary lesions in 241 patients; 63 patients had treate

108 er after successful PCI of all flow-limiting coronary lesions in 898 patients presenting with myocard

109 Thirty patients with at least 2 significant coronary lesions in different vessels were treated with

110 e and is expressed in the endothelium lining coronary lesions in mice and humans.

111 atomy and for early detection and grading of coronary lesions in non-diabetic patients.

112 t mice restored the ability of LCWE to cause coronary lesions in response to LCWE.

113 The development of coronary lesions in retransplanted isografts underlines

114 clerosis and prevents the development of new coronary lesions in smokers.

115 hy and the functional invasive assessment of coronary lesions in the work-up pre-TAVR.

116 ta play critical roles in the development of coronary lesions in this KD mouse model, blocked by IL-1

117 This problem affects studies of coronary lesions in which microcalcification processes a

118 liminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent

119 f WT and 100% of B cell(null) mice developed coronary lesions, indicating that T cells were required

120 When the culprit coronary lesion is distal to the right atrial (RA) branc

121 might propose that stenting all intermediate coronary lesions is an appropriate solution.

122 lantation of the DREAMS 2G device in de-novo coronary lesions is feasible, with favourable safety and

123 Optimal plaque preparation of calcified coronary lesions is key to prevent stent failure.

124 n the era of drug-eluting stents for diffuse coronary lesions, IVUS-guided percutaneous coronary inte

125 A total of 1043 patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm ve

126 Coronary lesions may impair the transmission of pressure

127 Borderline coronary lesions might become functionally significant a

128 coronary stent deployment have more complex coronary lesion morphology and a more complicated clinic

129 g-Eluting Stents in the Treatment of De Novo Coronary Lesions [NEXT]; NCT01373502).

130 ntly from the development of significant new coronary lesions, not initially severe enough to cause i

131 rteritis that histopathologically mimics the coronary lesions observed in KD patients.

132 racoronary physiological evaluation of >/= 1 coronary lesion of intermediate severity between April 1

133 Coronary lesions of intermediate stenosis demonstrate si

134 mposition and macrophage infiltration in the coronary lesions of patients with diabetes mellitus.

135 FFR was measured in vessels with coronary lesions of varying severity using a coronary pr

136 Most severely obstructive coronary lesions often remain quiescent and seldom desta

137 32, p = 0.005) and minimum lumen diameter of coronary lesions (OR: 1.83, 95% CI: 1.01 to 3.55, p = 0.

138 subjects with the TT or CT genotype had >/=1 coronary lesion (P=0.001).

139 Coronary lesions predominantly arose in the first 2-3 cm

140 Physiology assessment of coronary lesion prepercutaneous coronary intervention (P

141 e myocardial jeopardy index, total number of coronary lesions, prior coronary revascularization, and

142 One or more coronary lesions progressed in 16 of 34 lovastatin-treat

143 al coronary events was positively related to coronary lesion progression for all three surrogate end

144 The study included 150 coronary lesions proven to have moderate or severe steno

145 ed 2,487 patients with diabetes or high-risk coronary lesions randomizing to OCT- vs angiography-guid

146 s compared with bare metal stents in de novo coronary lesions reduces major adverse cardiac events in

147 The treatment of calcified coronary lesions requires optimal lesion preparation to

148 ed by the inability to identify intermediate coronary lesions responsible for ischemia.

149 Routine FFR assessment of coronary lesions safely changes management strategy in a

150 The assessment of functional coronary lesion severity using intracoronary physiologic

151 he Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study.

152 Use of CCTA for physiological evaluation of coronary lesion-specific ischemia may facilitate evaluat

153 trial recruited patients with de novo native coronary lesions suitable for 1- or 2-vessel treatment w

154 lternative strategy that can target multiple coronary lesions suitable for treatment with any approve

155 er to discriminate high-risk versus low-risk coronary lesions than [(18)F]FDG.

156 o accelerated atherosclerosis, especially of coronary lesions that are susceptible to rupture.

157 ses were possible both of differences in the coronary lesions that developed in a normolipidemic as c

158 Coronary lesions that later provoke acute myocardial inf

159 surgical treatment of significantly stenotic coronary lesions, the comprehensive and serial assessmen

160 inical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent h

161 to estimate the hemodynamic significance of coronary lesions, these pressure-derived indices provide

162 After treatment of all flow-limiting coronary lesions, three-vessel imaging was done with a c

163 stratification of patients with intermediate coronary lesions to appropriate therapy.

164 Thirty-one patients with de novo native coronary lesions treated with DCA in the Serial Ultrasou

165 Physicians tended to assess coronary lesions treated with percutaneous coronary inte

166 trasound was used to study 25 de novo native coronary lesions treated with single MultiLink stents wi

167 p at 8.3 months) were performed in 15 native coronary lesions treated with the QuaDS-QP2 stent.

168 ing outcomes of patients with single de novo coronary lesions treated with ZES or PES.

169 S (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) trial.

170 In all significant coronary lesions two observers measured the degree of st

171 Eighty-four stable patients with isolated coronary lesions underwent coronary stent deployment sta

172 receptor antagonist prevented LCWE-mediated coronary lesions up to 3 days after LCWE injection.

173 risk stratified for the presence of an acute coronary lesion using 4 easily measured variables.

174 nsitivity but improved specificity for right coronary lesions using attenuation/scatter correction me

175 or the detection of functionally significant coronary lesions using fractional flow reserve (FFR) as

176 gle-arm trial evaluating outcomes in de novo coronary lesions visually estimated to be 10 to 28 mm in

177 The mean length of the coronary lesions was 32 mm.

178 The functional relevance of 133 coronary lesions was assessed by FFR in 54 patients with

179 After adjustment, PCI of unstable coronary lesions was independently associated with impro

180 ity assessment of the detectability index of coronary lesions was performed.

181 The predictive performance for significant coronary lesions was poor across all electrocardiogram p

182 timal cutoff values to predict flow-limiting coronary lesion were 10 mm for lesion length, 1.8 mm2 fo

183 All coronary lesions were 80% to 95% stenosis in severity.

184 Overall, 765 coronary lesions were analyzed (culprit lesion precursor

185 IV trial, 1,314 patients with single de novo coronary lesions were assigned to implantation of the sl

186 Coronary lesions were classified as lesions with patholo

187 Before the introduction of DES, intermediate coronary lesions were commonly managed based on physiolo

188 Calcified coronary lesions were detected in all three image sets i

189 lysis also showed that CRP and the number of coronary lesions were independent predictors of risk of

190 Coronary lesions were induced in Yorkshire albino swine

191 Four groups of 5 balloon-induced coronary lesions were irradiated with 8, 12, 16, and 24

192 trial, in which 1,314 patients with de novo coronary lesions were randomized to either the paclitaxe

193 ts (aged >=18 years) with severely calcified coronary lesions were randomly assigned (1:1) to orbital

194 Patients with calcified coronary lesions were screened in 3 centers.

195 not adequately resolve complex Type B and C coronary lesions, which present unique challenges, requi

196 in 1,226 consecutive patients (1,259 native coronary lesions) who underwent a single vessel interven

197 g patients with stable angina and at least 1 coronary lesion with a fractional flow reserve </=0.80 w

198 as equivalent to that produced by stenting a coronary lesion with an instantaneous wave-free ratio of

199 Coronary lesions with a diameter narrowing >/=50% on vis

200 termined in normal and atherosclerotic human coronary lesions with a monoclonal antibody to human PLT

201 staining on the luminal endothelium of human coronary lesions with active monocyte entry.

202 nical interpretation of stenosis severity in coronary lesions with an independent assessment using qu

203 icient recipients had more severe aortic and coronary lesions with characteristic T cell infiltration

204 aortic stenosis, physiological assessment of coronary lesions with FFR before transcatheter aortic va

205 Management of coronary lesions with fractional flow reserve values in

206 ferred versus performed revascularization of coronary lesions with gray-zone fractional flow reserve

207 l versus performance of revascularization in coronary lesions with gray-zone fractional flow reserve.

208 for lesion preparation in severely calcified coronary lesions with high success rate, low procedural

209 A consecutive series of 456 coronary lesions with in-stent restenosis was evaluated

210 In a subgroup of 210 patients, focal coronary lesions with mild luminal narrowing were identi

211 to determine CAD-RADS 4 versus CAD-RADS 3 of coronary lesions with moderate to severe calcification.

212 PCI of coronary lesions with reduced fractional flow reserve im

213 Obstructive coronary lesions with reduced luminal dimensions may res

214 utaneous revascularization of de novo native coronary lesions with reference vessel diameters between

215 atherosclerotic lesions, we studied 20 human coronary lesions with techniques that have previously be

216 rest according to the likelihood of an acute coronary lesion would have significant utility.